Close Menu

Brandi Davis-Dusenbery

Mar 15, 2017

Seven Bridges has promoted Brandi Davis-Dusenbery to CEO. She succeeds Co-founder Deniz Kural, who is assuming the role of executive chairman of the board of directors. Davis-Dusenbery was the former senior vice president of science and product for Seven Bridges. Prior to Seven Bridges, she worked as a fellow at Harvard University's Department of Stem Cell and Regenerative Biology.

More Like This

Oct 18, 2019

Cadex Genomics: Kathy Hibbs

Cadex Genomics has appointed Kathy Hibbs as an independent director. Hibbs is currently chief legal and regulatory officer at 23andMe. Prior to joining 23andMe, Hibbs served as senior VP and general counsel at Genomic Health. Hibbs has also served in similar roles at Monogram Biosciences and Varian Medical Systems. 

Oct 16, 2019

Syapse: Thomas Brown

Syapse has hired Thomas Brown as its first chief medical officer, in charge of the company's research collaborations with health systems and other life sciences organizations. He also will be the primary liaison to regulatory agencies. Brown, an oncologist and cancer researcher, comes to Syapse after serving as executive director of the Swedish Cancer Institute at Providence St. Joseph Health in Seattle. He also cochaired the Providence St. Joseph Health Genomics Initiative.

Oct 15, 2019

Anixa BioSciences: Thomas Schlumpberger

Anixa Biosciences has appointed Thomas Schlumpberger as executive VP, diagnostics. Prior to joining Anixa Schlumpberger held executive roles with several diagnostic companies over the past 20 years, including InVitae, Affymetrix (now Thermo-Fisher Scientific), Inivata, and Singulex. 

Oct 15, 2019

Amalio Telenti, Brian Rubin, Holden Maecker, and Hamilton Moses

Caris Life Sciences has added four members  Amalio Telenti, Brian Rubin, Holden Maecker, and Hamilton Moses — to its scientific advisory board.

Telenti is chief data scientist and head of computational biology at Vir Biotechnology. He was previously a professor of genomics in the department of integrative structural and computational biology at Scripps Research and chief data scientist for Scripps Research Translational Institute. He also serves on advisory boards for the University of Lausanne's Center for Integrative Genomics, the Institute Pasteur Shanghai at the Chinese Academy of Sciences, and the Swiss Personalized Health Network.

Rubin is chair of the Robert J. Tomsich Pathology & Laboratory Medicine Institute at the Cleveland Clinic, as well as professor of pathology at the Cleveland Clinic Lerner College of Medicine. His research is focused on the diagnosis of soft tissues neoplasms and the analysis of aberrant signal pathways to identify new drug targets and therapeutic resistance mechanisms. 

Maecker is a professor of microbiology and immunology at Stanford University and director of Stanford's Human Immune Monitoring Center, conducting research on T cell response signatures and their association with protection from chronic pathogens and cancer.

Moses is a professor of neurology at the Johns Hopkins School of Medicine, and a life sciences management consultant, working through a company, Alerion Advisors, which he founded in 2002. He has also advised corporations, hospitals, foundations, and governments as a partner and senior advisor with the international strategy firm, The Boston Consulting Group. He previously served as chief physician and chief operating officer of the Johns Hopkins Hospital and Health System, interim chief of psychiatry of the Partners Health Care System and McLean Hospital in Boston, and professor of business at the Darden School of the University of Virginia.

Oct 15, 2019

Fluxergy: Ali Tinzali

Fluxergy, an Irvine, California-based developer of point-of-care diagnostics systems, has appointed Ali Tinzali as chief commercial officer. Tinzali joins Fluxergy from Hewlett-Packard, where he led corporate-wide global strategy for healthcare and life sciences. He has also worked in corporate development at Applied Biosystems (now Thermo Fisher Scientific). He also worked for Sony where he helped build a healthcare consumables business that was acquired by Stratec.

Oct 10, 2019

Stilla Technologies: Ruth Szebries

Stilla Technologies has appointed Ruth Szebries as general manager and vice president of commercial operations for its newly established US subsidiary in Beverly, Massachusetts. Szebries will oversee operations in the Americas for the Paris, France-based digital PCR developer. Her previous life science industry experience includes positions at Applied Biosystems and Beckman Coulter, leading the US subsidiaries of BGI and Exiqon, and serving for three years at Qiagen, most recently as that firm's senior director for global market development.

Oct 08, 2019

Grail: Matthew Young

Grail has appointed Matthew Young as chief operating officer. Young joins Grail from Jazz Pharmaceuticals, where he most recently served as executive VP and CFO. Prior to Jazz, Young worked in investment banking for about 20 years in positions at Barclays Capital, Citigroup Global Markets, and Lehman Brothers. He currently is a board member at PRA Health Sciences. Young is also a lead independent director and chairman of the audit committee of CytomX Therapeutics. 

Oct 08, 2019

Biodesix: James Jett

Biodesix has appointed James Jett as chief medical officer. Jett previously served as CMO at Oncoimmune. Before Onocimmune, Jett worked as a professor of medicine at the Mayo Medical School and the University of Pittsburgh. Jett has also served as a consultant for the National Cancer Institute and as the editor in chief of the Journal of Thoracic Oncology from 2006 to 2013. 

Oct 04, 2019

Grail: Marissa Song

Grail has appointed Marissa Song as its general counsel and corporate secretary. Prior to Grail, Song worked at Gilead Sciences for 14 years, where she most recently served as VP of corporate legal. Before Gilead, Song was a corporate associate at Latham & Watkins LLP. She also currently serves on the board of the Disability Rights Legal Center.

Oct 04, 2019

Meridian Bioscience: Bryan Baldasare

Meridian has appointed Bryan Baldasare to chief financial officer. He was previously the interim CFO, corporate controller, and treasurer and is currently also the executive vice president and chief accounting officer. Baldasare has been with Meridian since 2000, and before that he was a senior audit manager at Arthur Andersen LLP. 

Oct 02, 2019

NanoString Technologies: Mark Winham

Nanostring has appointed Mark Winham as senior vice president of operations. Winham worked for more than 10 years in manufacturing for Applied Biosystems and Life Technologies, serving in roles of increasing responsibility from senior director to vice president of global manufacturing. More recently, he served as chief scientific and operating officer at Wamberg Genomic Advisors. Prior to that, he was chief operating office for Human Longevity, and also previously served as COO of Millennium Health.

Oct 01, 2019

Precision Biosciences: Nicholas Riddle

Precision Biosciences announced today that it has appointed Nicholas Riddle as VP, financial strategy and investor relations. Prior to Precision, Riddle served as executive director at J.P. Morgan. Before that, Riddle held the role of public market equity analyst at York Capital Management.

Sep 26, 2019

Becton Dickinson: Vincent Forlenza, Thomas Polen

Becton Dickinson announced that Vincent Forlenza will retire from his position as of Jan. 28, 2020. Forlenza, who has been with BD for 40 years and has led the company as CEO since 2011, will continue to serve as executive chairman of its board of directors. Thomas Polen, the firm's chief operating officer, will take over as CEO. 

Sep 26, 2019

Cofactor Genomics: Natalie LaFranzo

Cofactor Genomics has promoted Natalie LaFranzo to Vice President of Market Development. She has been with the company for three years. Previously, she held roles in product management at Horizon Discovery and in marketing and communications at Red Rock Labs. LaFranzo will also head Cofactor's new predictive immune modeling center in Cambridge, Massachusetts. The facility will be the company's hub for the research and operations team working with Boston-based pharma, RNA, precision medicine, and immunotherapy companies. 

Sep 25, 2019

Myriad Genetics: Colleen Reitan, Lee Newcomer

Myriad Genetics has elected Colleen Reitan and Lee Newcomer to its board of directors.

Reitan has spent more than 32 years working in the Blue Cross Blue Shield system, most recently as president of plan operations for Health Care Service Corporation (HCSC), a health plan covering 16 million lives. Prior to BCBS, Reitan held several roles of increasing responsibility including executive VP and chief operating officer for HCSC and president and chief operating officer of BCBS of Minnesota. She currently serves on the boards of Alnylam Pharmaceuticals and Cricket Health.

Newcomer is a board-certified oncologist who most recently served as senior VP of oncology and genetics for UnitedHealthcare. Previously, he was chief medical officer and senior VP of health policy and strategy at UnitedHealth Group. He also served as chief medical officer at Vivius. Newcomer currently serves on the board of Cellworks Group and Intervention Insights.

As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.

BBC News says the uncertainty over Brexit is affecting science funding in the UK.

A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.

In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.